Catatan sumber primer
PenentuHasil topline
Invivyd VYD2311 DECLARATION Data Fase 3 topline diharapkan Q3 2026
Uji coba pivotal DECLARATION telah selesai pendaftarannya dengan data top-line direncanakan pada akhir Q3 2026 untuk mendukung potensi pengajuan BLA. Uji coba LIBERTY Phase 3 juga telah selesai dosis dengan data top-line diantisipasi pada akhir Q3 2026.
Fakta utama
- Diajukan
- 13 Agu 2026, 20.11
- Peristiwa
- Hasil topline
- Arah
- Netral
- Perusahaan
IVVDInvivyd- Aset
- pemivibart
- Sumber
- SEC 8-K
- Keyakinan
- Bersumber
Kutipan sumber
EX-99.1 2 ivvd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million • Completed rapid enrollment in VYD2311 DECLARATION clinical trial expansion cohort and LIBERTY clinical trial, driven by strong subject demand • DECLARATION pivotal clinical trial enrollment is complete; the ongoing study is approaching its planned analysis, and in lieu of a Q2 2026 quarterly earnings call, Invivyd plans to hold an investor call post study completion • LIBERTY study fully dosed with top-line data anticipated in late Q3 2026 • Strong balance sheet with Q2 2026 ending cash and